×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Metformin for Parkinson's Disease - Phase 2/3 Trial (NCT0722
clinical
1,298 words
KG: metformin
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
topic:parkinsons
topic:metformin
topic:ampk-activator
Contents
Metformin for Parkinson's Disease - Phase 2/3 Trial (NCT07229651)
Knowledge Graph
Related Hypotheses (30)
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.70
Transcriptional Autophagy-Lysosome Coupling
Score: 0.68
APOE-Dependent Autophagy Restoration
Score: 0.63
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.59
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.57
Selective HDAC3 Inhibition with Cognitive Enhancement
Score: 0.56
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
Retinal Vascular Microcirculation Rescue
Score: 0.54
Vagal Afferent Microbial Signal Modulation
Score: 0.52
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Membrane Cholesterol Gradient Modulators
Score: 0.52
Stress Granule Phase Separation Modulators
Score: 0.49
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Lysosomal Enzyme Trafficking Correction
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.48
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.48
Circadian Rhythm Entrainment of Reactive Astrocytes
Score: 0.48
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48
Arginine Methylation Enhancement Therapy
Score: 0.46
Lysosomal Membrane Repair Enhancement
Score: 0.45
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43
Low Complexity Domain Cross-Linking Inhibition
Score: 0.42
Brain Insulin Resistance with Glucose Transporter Dysfunctio
Score: 0.40
The Glial Ketone Metabolic Shunt Hypothesis
Score: 0.40
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.39
Show 25 more
Related Analyses (28)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Show 23 more
Related Experiments (30)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40
Show 25 more
See Also (4)
Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: associated_with
Alzheimer Indonesia
institution · KG edge: associated_with
Autophagy Enhancement Drug Screening for Neurodegenerat
experiment · KG edge: activates
AMPK (AMP-Activated Protein Kinase)
entity · KG edge: activates
Knowledge Graph (12 edges)
metformin
activates
AMPK
metformin
regulates
BMAL1
metformin
treats
Parkinson's disease
metformin
treats
Alzheimer's disease
metformin
treats
type 2 diabetes mellitus
metformin
inhibits
reactive oxygen species production
metformin
treats
epilepsy
metformin
therapeutic_target
Alzheimer's disease
metformin
treats
insulin sensitivity
metformin
inhibits
astrocyte senescence